Clinical phenotype, atrophy, and small vessel disease in APOE ε2 carriers with Alzheimer disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Objective To examine the clinical phenotype, gray matter atrophy patterns, and small vessel disease in patients who developed prodromal or probable Alzheimer disease dementia, despite carrying the protective APOEε2 allele. Methods We included 36 β-amyloid-positive (by CSF or PET) APOEε2 carriers (all ε2/ε3) with mild cognitive impairment or dementia due to Alzheimer disease who were matched for age and diagnosis (ratio 1:2) to APOEε3 homozygotes and APOEε4 carriers (70% ε3/ε4 and 30% ε4/ε4). We assessed neuropsychological performance across 4 cognitive domains (memory, attention, executive, and language functions), performed voxelwise and region of interest analyses of gray matter atrophy on T1-weighted MRI, used fluid-attenuated inversion recovery images to automatically quantify white matter hyperintensity volumes, and assessed T2*-weighted images to identify microbleeds. Differences in cognitive domain scores, atrophy, and white matter hyperintensities between ε2 carriers, ε3 homozygotes, and ε4 carriers were assessed using analysis of variance analyses, and Pearson χ2 tests were used to examine differences in prevalence of microbleeds. Results We found that ε2 carriers performed worse on nonmemory domains compared to both ε3 homozygotes and ε4 carriers but better on memory compared to ε4 carriers. Voxelwise T1-weighted MRI analyses showed asymmetric (left > right) temporoparietal-predominant atrophy with subtly less involvement of medial–temporal structures in ε2 carriers compared to ε4 carriers. Finally, ε2 carriers had larger total white matter hyperintensity volumes compared to ε4 carriers (mean 10.4 vs 7.3 mL) and a higher prevalence of microbleeds compared to ε3 homozygotes (37.5% vs 18.3%). Conclusion APOEε2 carriers who develop Alzheimer disease despite carrying the protective allele display a nonamnestic clinical phenotype with more severe small vessel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“The e4 allele is the main genetic risk factor for sporadic Alzheimer disease (AD).(3,4) In contrast, carrying an APOEe2 allele is a protective factor against AD and reduces the risk for developing AD by about half.”
BackgroundTau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185 · cited 1×
“The sparing of the MTL in e2 carriers relative to e4 carriers could be explained by the susceptibility of the MTL to taumediated atrophy,(48) as recent PET studies suggested increased tau pathology in MTL regions in e4 carriers.(37) The asymmetric (left > right) atrophy pattern in e2 carriers showed some clinical rele…”
BackgroundSelf-citationApolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Ossenkoppele, R., Pijnenburg, Y. A. L., Perry, D. C., Cohn-Sheehy, B. I., Scheltens, N. M. E., Vogel, J. W., Kramer, J. H., van der Vlies, A. E., Joie, R. L., Rosen, H. J., et al. (2015) · Brain · doi:10.1093/brain/awv191 · Cited by 548
Self-citationApolipoprotein E and Cognitive Performance: A Meta-Analysis.
Small, B. J., Rosnick, C. B., Fratiglioni, L., & Bäckman, L. (2004) · Psychology and Aging · doi:10.1037/0882-7974.19.4.592 · Cited by 447
Association of Cerebral Microbleeds With Cognitive Decline and Dementia
Akoudad, S., Wolters, F. J., Viswanathan, A., de Bruijn, R. F., van der Lugt, A., Hofman, A., Koudstaal, P. J., Ikram, M. A., & Vernooij, M. W. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1017 · Cited by 403
Association of apolipoprotein E ϵ2 and vasculopathy in cerebral amyloid angiopathy
Greenberg, S. M., Vonsattel, J.-P. G., Segal, A. Z., Chiu, R. I., Clatworthy, A. E., Liao, A., Hyman, B. T., & Rebeck, G. W. (1998) · Neurology · doi:10.1212/wnl.50.4.961 · Cited by 267
Cognitive Phenotypes in Alzheimer's Disease and Genetic Risk
Snowden, J. S., Stopford, C. L., Julien, C. L., Thompson, J. C., Davidson, Y., Gibbons, L., Pritchard, A., Lendon, C. L., Richardson, A. M., Varma, A., et al. (2007) · Cortex · doi:10.1016/s0010-9452(08)70683-x · Cited by 254
Cited by
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
A clinical-radiological framework of the right temporal variant of frontotemporal dementia
Ulugut Erkoyun, H., Groot, C., Heilbron, R., Nelissen, A., van Rossum, J., Jutten, R., Koene, T., van der Flier, W. M., Wattjes, M. P., Scheltens, P., et al. (2020) · Brain · doi:10.1093/brain/awaa225 · Cited by 161
“…body magnetic resonance system (Siemens Magnetom Impact, Avanto and Sonata, GE Healthcare Signa HDXT, Discovery MR750, GE Medical Systems; Ingenuity TF PET/MR, Philips Medical Systems; Titan, Toshiba Medical Systems), using previously described protocols (Ten Kate et al., 2017; Groot et al., 2018).”
MethodSelf-citationIngala, S., Mazzai, L., Sudre, C. H., Salvadó, G., Brugulat-Serrat, A., Wottschel, V., Falcon, C., Operto, G., Tijms, B., Gispert, J. D., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.015 · Cited by 25
“The only other literature report that investigated this relation showed an increased prevalence of CMBs in APOE-ε2 carriers compared to APOE-ε3 homozygous in a small sample of subjects with mild cognitive impairment or Alzheimer’s dementia (Groot et al., 2018).”
ResultSelf-citation
Metadata
- Authors
- Groot, C., Sudre, C. H., Barkhof, F., Teunissen, C. E., van Berckel, B. N. M., Seo, S. W., Ourselin, S., Scheltens, P., Cardoso, M. J., van der Flier, W. M., & Ossenkoppele, R.
- Venue
- Neurology
- Published
- 2018-11-13
- Volume
- 91
- Issue
- 20
- Pages
- e1851-e1859
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2896420254
- Cited by
- 53
- References
- 15
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical phenotype, atrophy, and small vessel disease in APOE ε2 carriers with Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000006503
- The paper
- Groot, C., Sudre, C. H., Barkhof, F., Teunissen, C. E., van Berckel, B. N. M., Seo, S. W., Ourselin, S., Scheltens, P., Cardoso, M. J., van der Flier, W. M., & Ossenkoppele, R. (2018). Clinical phenotype, atrophy, and small vessel disease in APOE ε2 carriers with Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000006503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.